Melanoma trials in Italy

In Italy 62 Also abroad 579

62 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Where
Candiolo, Milan, Naples, Rozzano
Age
18 years and over
People
15 worldwide
Run by
Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Bergamo, Milan, Naples, Perugia, Siena
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
No phaseNot yet taking people in Italy
Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers
Where
Milan
Age
18 years and over
People
360
Run by
European Institute of Oncology
See details and how to joinNCT07815873
Phase 1Not yet taking people in Italy
A Multicentre, open label, Phase I-Ib Clinical Trial Combining Melanoma-Specific Peptide Vaccination (UniCanVax) and Anti PD-1 Inhibitor (Nivolumab) in Immune Checkpoint Blockade Refractory Metastatic or Unresectable Stage III/IV Melanoma Patients
Where
Milan, Naples, Padova, Perugia, Rozzano
Age
18 years and over
People
25
Run by
Humanitas Mirasole S.p.A.
See details and how to join2025-524486-25-00 · EU 2025-524486-25-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Bergamo, Brescia, Ferrara, Florence, Milan, Modena, Pavia, Verona
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 3Taking people
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
Where
Catanzaro, Siena
Age
18 years and over
People
632 worldwide
Run by
mAbxience Research S.L.
See details and how to joinNCT07221734
Phase 1Not yet taking people in Italy
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT
Where
Meldola, Milan, Naples, Padova, Perugia, Rome
Age
18 years and over
People
80
Run by
Fondazione Melanoma Onlus
See details and how to join2024-519010-31-00 · EU 2024-519010-31-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Bergamo, Genova, Naples, Verona
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Candiolo, Milan, Naples, Rome, Rozzano
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1Taking people
A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting
Where
Ancona, Brescia, Naples, Rome
Age
18 years and over
People
83 worldwide
Run by
H e x a l AG
See details and how to join2025-521919-39-00 · EU 2025-521919-39-00
Phase 1/2Taking people
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Where
Meldola, Milan, Naples, Roma, Rozzano
Age
18 years and over
People
1,438 worldwide
Run by
BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00
No phaseNot yet taking people in Italy
Dermatological Effects and Quality of Life in Oncology Patients
Where
Milan
Age
18 years and over
People
300
Run by
European Institute of Oncology
See details and how to joinNCT07869186
Phase 2Taking people
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
Where
Naples
Age
18 years to 120 years
People
218 worldwide
Run by
Melanoma Institute Australia
See details and how to joinNCT03340129 · EU 2024-518545-13-00
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Alexandria, Ancona, Bari, Bergamo, Candiolo, Genoa, Messina, Milan, Modena, Padova, Rome, San Giovanni Rotondo, Siena, Trento
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 2Not yet taking people in Italy
PHOENIX - ECP: Extracorporeal PHotopheresis for immune-related cOlitis and/or hEpatitis in advanced melaNoma with inadequate response to steroId eXposure
Where
Bari, Milan, Naples
Age
18 years and over
People
46 worldwide
Run by
Therakos Europe Limited
See details and how to join2026-526261-14-00 · EU 2026-526261-14-00
Phase 2Taking people
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Where
Milan, Naples, Padova, Roma
Age
18 years and over
People
160 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06961006
Phase 3Taking people
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Where
Aviano, Meldola, Milan, Naples, Pisa, Siena
Age
18 years to 70 years
People
670 worldwide
Run by
Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00
No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
Meldola, Reggio Emilia, Roma
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444
No phaseTaking people
MELanoma Brain Metastasis Treated With CYberknife
Where
Milan
Age
18 years and over
People
50
Run by
European Institute of Oncology
See details and how to joinNCT07691255
Phase 1Taking people
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Where
Naples
Age
18 years and over
People
400 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT04913285
Phase 2Taking people
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
Where
Naples
Age
18 years and over
People
162 worldwide
Run by
Philogen S.p.A.
See details and how to joinNCT06284590 · EU 2024-519326-20-00
Phase 3Enrolling by invitation
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
Where
Florence, Milan, Rome
Age
18 years and over
People
100 worldwide
Run by
Aura Biosciences
See details and how to joinNCT07338968 · EU 2025-524405-33-00
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Candiolo, Milan, Naples, Roma, Rozzano, Siena
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 2Taking people
Phase II study of Roginolisib in UM patients
Where
Bari, Naples, Padova, Rozzano, Siena
Age
18 years and over
People
43 worldwide
Run by
iOnctura SA
See details and how to join2024-514333-37-00 · EU 2024-514333-37-00
Phase 3Taking people
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Where
Bari, Milan, Modena, Naples, Perugia, Rome, Siena
Age
12 years and over
People
400 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06264180 · EU 2023-508612-29-00